We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
InMode (INMD) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, InMode (INMD - Free Report) closed at $24.94, marking a +1.96% move from the previous day. The stock lagged the S&P 500's daily gain of 3.06%. At the same time, the Dow added 2.39%, and the tech-heavy Nasdaq gained 3.95%.
Heading into today, shares of the maker of cosmetic surgery devices had gained 54.42% over the past month, outpacing the Medical sector's gain of 3.13% and the S&P 500's gain of 2.36% in that time.
INMD will be looking to display strength as it nears its next earnings release, which is expected to be May 6, 2020.
INMD's full-year Zacks Consensus Estimates are calling for earnings of $0.73 per share and revenue of $115.77 million. These results would represent year-over-year changes of -55.21% and -25.96%, respectively.
Investors might also notice recent changes to analyst estimates for INMD. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 60.75% lower within the past month. INMD is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note INMD's current valuation metrics, including its Forward P/E ratio of 33.51. This valuation marks a premium compared to its industry's average Forward P/E of 27.65.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 41, which puts it in the top 17% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
InMode (INMD) Gains But Lags Market: What You Should Know
In the latest trading session, InMode (INMD - Free Report) closed at $24.94, marking a +1.96% move from the previous day. The stock lagged the S&P 500's daily gain of 3.06%. At the same time, the Dow added 2.39%, and the tech-heavy Nasdaq gained 3.95%.
Heading into today, shares of the maker of cosmetic surgery devices had gained 54.42% over the past month, outpacing the Medical sector's gain of 3.13% and the S&P 500's gain of 2.36% in that time.
INMD will be looking to display strength as it nears its next earnings release, which is expected to be May 6, 2020.
INMD's full-year Zacks Consensus Estimates are calling for earnings of $0.73 per share and revenue of $115.77 million. These results would represent year-over-year changes of -55.21% and -25.96%, respectively.
Investors might also notice recent changes to analyst estimates for INMD. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 60.75% lower within the past month. INMD is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note INMD's current valuation metrics, including its Forward P/E ratio of 33.51. This valuation marks a premium compared to its industry's average Forward P/E of 27.65.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 41, which puts it in the top 17% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.